Enalapril
Based on 13 publication(s) in Google Scholar
Enalapril (MK-421) is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.96%
- CAS 番号: 75847-73-3
- 分子式: C20H28N2O5
- 分子量:376.45
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Angiogenesis-Related Compound Library
HY-L088
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
MedChemExpress（MCE）の使用を引用している文献 Enalapril
More- Nat Commun. 2023 May 2;14(1):2523. [Abstract]
- Environ Pollut. 2019 Apr:247:927-934. [Abstract]
- Int J Nanomedicine. 2025 Oct 27:20:12993-13006. [Abstract]
- Elife. 2025 Aug 28:14:RP104774. [Abstract]
- Toxicology. 2023 Mar 1:486:153442. [Abstract]
- Toxicol Appl Pharmacol. 2026 Mar 27:511:117802. [Abstract]
- Cardiooncology. 2025 Nov 13;11(1):106. [Abstract]
- Ren Fail. 2023;45(2):2253924. [Abstract]
- Toxicol Lett. 2019 Jul:309:42-50. [Abstract]
- Am J Transl Res. 2022 Jan 15;14(1):211-222. [Abstract]
- Int J Clin Exp Pathol. 2020 May 1;13(5):827-836. [Abstract]
- bioRxiv. 2025 Jun 27:2025.06.24.660441. [Abstract]
- bioRxiv. 2024 November 28.
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
4500 μM
Compound: Enalapril
|
TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells
TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells
|
[PMID: 10052994] |
| CHO | IC50 |
15 mM
Compound: Enalapril
|
TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells
TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells
|
[PMID: 9706043] |
| HEK293 | IC50 |
>500 μM
Compound: enalapril
|
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
|
[PMID: 23241029] |
Enalapril (10-20 μM) has an antiarrhythmic effect in ultrafiltered PV sleeve preparation isolated from canine hearts which can inhibit EAD and DAD-induced activity[1].
Enalapril (50 μM, 24 hours) inhibits the induction of apoptosis by patient serum only when used prior to treatment of HUVEC with Alzheimer's disease (AD) serum[2].
Pure Enalapril has better thermal stability than pure Enalapril[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein ECs (HUVECs)
-
Concentration:50 μM
-
Incubation Time:24 hours
-
Result:Inhibited the induction of apoptosis by patient serum.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male NMRI mice 20-40 g[4]
-
Dosage:0.03 mg/kg
-
Administration:Intraperitoneal injection; once
-
Result:Reduced the area of middle cerebral artery infarction in mice at 0.03 mg/kg.
化学情報
-
CAS 番号 75847-73-3
-
性状 Solid
-
分子量 376.45
-
分子式 C20H28N2O5
-
Color White to off-white
-
SMILES
O=C(O)[C@H]1N(C([C@H](C)N[C@H](C(OCC)=O)CCC2=CC=CC=C2)=O)CCC1
-
別名
MK-421
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice. [Abstract]2023 May 2;14(1):2523. PMID: 37130842 -
Environ Pollut
Di-(2-ethylhexyl) phthalate induced an increase in blood pressure via activation of ACE and inhibition of the bradykinin-NO pathway. [Abstract]2019 Apr:247:927-934. PMID: 30823347 -
Int J Nanomedicine
Engineering Multifunctional Nanozymes to Reprogram Oxidative Stress and Inflammation in Chronic Wounds. [Abstract]2025 Oct 27:20:12993-13006. PMID: 41179976 -
Elife
Enalapril mitigates senescence and aging-related phenotypes in human cells and mice via pSmad1/5/9-driven antioxidative genes. [Abstract]2025 Aug 28:14:RP104774. PMID: 40874922 -
Toxicology
2023 Mar 1:486:153442. PMID: 36706861 -
Toxicol Appl Pharmacol
Saikosaponin D protects against isoproterenol-induced kidney injury in rats by regulating the intrarenal renin-angiotensin system. [Abstract]2026 Mar 27:511:117802. PMID: 41903810 -
Cardiooncology
Breast cancer progression in the presence of treated and untreated left ventricular dysfunction. [Abstract]2025 Nov 13;11(1):106. PMID: 41233850 -
Ren Fail
Crocin improves the renal autophagy in rat experimental membranous nephropathy via regulating the SIRT1/Nrf2/HO-1 signaling pathway. [Abstract]2023;45(2):2253924. PMID: 37724538 -
Toxicol Lett
Exposure to diisononyl phthalate induced an increase in blood pressure through activation of the ACE/ AT1R axis and inhibition of NO production. [Abstract]2019 Jul:309:42-50. PMID: 30940551 -
Am J Transl Res
Combination therapy with artemether and enalapril improves type 1 diabetic nephropathy through enhancing antioxidant defense. [Abstract]2022 Jan 15;14(1):211-222. PMID: 35173839 -
Int J Clin Exp Pathol
2020 May 1;13(5):827-836. PMID: 32509053 -
bioRxiv
Flow-sensitive HEG1 controls eNOS activity to prevent endothelial dysfunction, hypertension, and atherosclerosis. [Abstract]2025 Jun 27:2025.06.24.660441. PMID: 40667131 -
溶剤 & 溶解度
DMSO : 100 mg/mL (265.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (132.82 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (13.28 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (13.28 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Serge Sicouri, et al. Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol. 2011 Jun;22(6):698-705. [Content Brief]
[3]. Talita A Cunha, et al. Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms. AAPS PharmSciTech. 2013 Sep;14(3):1150-7. [Content Brief]
[4]. A Ravati, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373(1):21-33. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.6564 mL | 13.2820 mL | 26.5640 mL | 66.4099 mL |
| 5 mM | 0.5313 mL | 2.6564 mL | 5.3128 mL | 13.2820 mL | |
| 10 mM | 0.2656 mL | 1.3282 mL | 2.6564 mL | 6.6410 mL | |
| 15 mM | 0.1771 mL | 0.8855 mL | 1.7709 mL | 4.4273 mL | |
| 20 mM | 0.1328 mL | 0.6641 mL | 1.3282 mL | 3.3205 mL | |
| 25 mM | 0.1063 mL | 0.5313 mL | 1.0626 mL | 2.6564 mL | |
| 30 mM | 0.0885 mL | 0.4427 mL | 0.8855 mL | 2.2137 mL | |
| 40 mM | 0.0664 mL | 0.3320 mL | 0.6641 mL | 1.6602 mL | |
| 50 mM | 0.0531 mL | 0.2656 mL | 0.5313 mL | 1.3282 mL | |
| 60 mM | 0.0443 mL | 0.2214 mL | 0.4427 mL | 1.1068 mL | |
| 80 mM | 0.0332 mL | 0.1660 mL | 0.3320 mL | 0.8301 mL | |
| 100 mM | 0.0266 mL | 0.1328 mL | 0.2656 mL | 0.6641 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz